EoCene Ltd. (EOCN)
Eocene Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.
Sector: Pharmaceutical Preparations
Industry: Medical - Pharmaceuticals
Eocene Ltd.
EoCene Ltd. (EOCN) dilution facts from SEC filings
Snapshot as of Dec 31, 2025, built from 47 SEC filings.
- At-the-market (ATM) program
- No active program in the filings reviewed
- Warrants outstanding
- 1 warrant series recorded as outstanding
- Most recent offering
- Not measured
Check another stock for dilution
Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.